New Clinical Trial to Test Effectiveness of Vorinostat

According to a recent press release on PR Web, a Phase III clinical trial is underway at the National Institutes of Health Clinical Center in Maryland to determine the effectiveness of the drug Vorinostat in treating patients with pleural malignant mesothelioma.

Manufactured by Merck, Vorinostat marketed under the brand name Zolinza is a prescription medicine most commonly used to treat cutaneous T-cell lymphoma in patients where the cancer worsens, does not go away, or returns after treatment with other medicines. Zolinza is taken in capsule form.

According to the article, candidates for the trial must have a histologically or cytologically confirmed diagnosis of pleural mesothelioma, which may be of the epithelial, sarcomatoid or mixed sub-type. All patients must also have previously gone through 1 or 2 standard systemic mesothelioma treatments that included pemetrexed disodium and either cisplatin or carboplatin.

The clinic hopes to enroll 660 mesothelioma patients in this trial, which will also attempt to ascertain the level of toxicity as well as any side effects that occur in patients who have been prescribed Vorinostat and compare these results against those of patients who have been administered a placebo.

Leave a Reply